微小残留病检测在淋巴系统恶性肿瘤精准医学中的研究进展  

Progress of minimal residual disease detection in precision medicine of lymphatic malignancies

作　　者：邱林[1] 马军[1] Qiu Lin;Ma Jun(Harbin Institute of Hematology and Oncology,Harbin 100010,China)

机构地区：[1]哈尔滨血液病肿瘤研究所,哈尔滨100010

出　　处：《白血病．淋巴瘤》2024年第3期142-147,共6页Journal of Leukemia & Lymphoma

摘　　要：随着淋巴系统恶性肿瘤精准治疗的不断进步,微小残留病(MRD)在其疗效评价、预后判断、治疗决策指导和复发预测等方面发挥着越来越重要的作用。目前,每年发表的涉及MRD检测相关血液系统恶性肿瘤文章近千篇。2023年第65届美国血液学会(ASH)年会上,涉及MRD检测在淋巴系统恶性肿瘤诊疗中应用的投稿近500篇,涵盖的内容非常广泛。文章遴选MRD检测在急性淋巴细胞白细胞、慢性淋巴细胞白细胞、多发性骨髓瘤和淋巴瘤中相关研究的口头报告作一介绍。With the great progress of precise medicine for lymphatic malignancies,minimal residual diseases(MRD)play an increasingly important role in their evaluation of treatment response,prognosis judgement,treatment decision guidance,and recurrence prediction.At present,nearly a thousand articles on hematological malignancies related to MRD detection are published annually.At the 65th American Society of Hematology annual meeting in 2023,nearly 500 articles on the application of MRD detection in the diagnosis and treatment of lymphatic malignancies cover a wide and rich range of content.This paper reviews the oral reports of MRD detection in acute lymphocytic leukemia,chronic lymphocytic leukemia,multiple myeloma and lymphoma.

关 键 词：淋巴系统疾病 微小残留病 多参数流式细胞术 二代测序 循环肿瘤DNA 

分 类 号：R733[医药卫生—肿瘤]